• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.

作者信息

Kool Ronald, João Mansure José, Kassouf Wassim

机构信息

Experimental Surgery, McGill University Health Centre, Montreal, Canada.

Department of Urology, McGill University Health Centre, McGill University, Montreal, Canada.

出版信息

Transl Androl Urol. 2019 Jul;8(Suppl 3):S325-S328. doi: 10.21037/tau.2019.05.12.

DOI:10.21037/tau.2019.05.12
PMID:31392159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6642967/
Abstract
摘要

相似文献

1
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.肌肉浸润性膀胱癌的分子亚型、肿瘤浸润及三联疗法：问题多于答案
Transl Androl Urol. 2019 Jul;8(Suppl 3):S325-S328. doi: 10.21037/tau.2019.05.12.
2
Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.比较根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌老年患者的生存结局和成本。
JAMA Surg. 2018 Oct 1;153(10):881-889. doi: 10.1001/jamasurg.2018.1680.
3
Trimodal therapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌的三联疗法。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1219-1229. doi: 10.1080/14737140.2018.1535314. Epub 2018 Oct 17.
4
Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer.质子束治疗对肌层浸润性膀胱癌进行三联保膀胱治疗的长期单机构经验。
Jpn J Clin Oncol. 2017 Jan;47(1):67-73. doi: 10.1093/jjco/hyw151. Epub 2016 Oct 13.
5
The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer.采用实时肿瘤追踪放疗系统行保留膀胱的三联疗法治疗肌层浸润性膀胱癌的最新结果。
Jpn J Clin Oncol. 2020 May 5;50(5):609-616. doi: 10.1093/jjco/hyz211.
6
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?系统评价和荟萃分析：三联疗法与根治性膀胱切除术治疗肌层浸润性膀胱癌的比较：当前证据质量是否足以得出明确结论？
PLoS One. 2019 Apr 29;14(4):e0216255. doi: 10.1371/journal.pone.0216255. eCollection 2019.
7
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.局部肌层浸润性膀胱癌行三联疗法与根治性膀胱切除术的疗效比较。
Eur Urol. 2017 Oct;72(4):483-487. doi: 10.1016/j.eururo.2017.03.038. Epub 2017 Apr 12.
8
Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.肌肉浸润性膀胱癌三联疗法与根治性膀胱切除术的疗效比较：倾向评分匹配分析
Oncotarget. 2017 Mar 25;8(40):68996-69004. doi: 10.18632/oncotarget.16576. eCollection 2017 Sep 15.
9
Combined modality treatment with bladder preservation for muscle invasive bladder cancer.联合治疗保膀胱疗法治疗肌层浸润性膀胱癌。
Urol Oncol. 2010 Jan-Feb;28(1):14-20. doi: 10.1016/j.urolonc.2008.07.005. Epub 2008 Sep 24.
10
Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.膀胱保留疗法：文献综述及三联疗法的未来方向
Curr Urol Rep. 2018 Nov 3;19(12):108. doi: 10.1007/s11934-018-0859-z.

引用本文的文献

1
Deciphering riddles in molecular subtyping of bladder cancer.解读膀胱癌分子亚型中的谜题。
Asian J Urol. 2025 Apr;12(2):217-231. doi: 10.1016/j.ajur.2024.09.006. Epub 2024 Dec 5.
2
Bladder cancer under staging: still unavoidable?膀胱癌分期不足：仍不可避免吗？
Transl Androl Urol. 2019 Dec;8(Suppl 5):S486-S487. doi: 10.21037/tau.2019.09.44.

本文引用的文献

1
Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer.作者回复：关于阿南雅·乔杜里、彼得·J·霍斯金。肌层浸润性膀胱癌的预测生物标志物：寻找圣杯仍在继续。《欧洲泌尿外科杂志》2019年；76卷：69 - 70页：迈向基于生物标志物的肌层浸润性膀胱癌管理
Eur Urol. 2019 Jul;76(1):71-72. doi: 10.1016/j.eururo.2019.03.009. Epub 2019 Mar 23.
2
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.免疫和基质浸润对肌层浸润性膀胱癌保膀胱三联疗法后结局的影响。
Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.
3
Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis.肿瘤浸润淋巴细胞在肝细胞癌中的预后价值：一项荟萃分析。
Medicine (Baltimore). 2018 Dec;97(50):e13301. doi: 10.1097/MD.0000000000013301.
4
Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.肿瘤基质浸润肥大细胞可预测肌层浸润性膀胱癌患者的预后及辅助化疗疗效。
Oncoimmunology. 2018 Aug 1;7(9):e1474317. doi: 10.1080/2162402X.2018.1474317. eCollection 2018.
5
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.TGFβ 通过促使 T 细胞排除而减弱肿瘤对 PD-L1 阻断的反应。
Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.
6
A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.一项关于肌肉浸润性膀胱癌接受三联疗法以及接受或不接受新辅助化疗的根治性膀胱切除术后肿瘤学长期结局的系统评价和荟萃分析。
Urol Oncol. 2018 Feb;36(2):43-53. doi: 10.1016/j.urolonc.2017.10.002. Epub 2017 Nov 6.
7
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
8
Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.炎症细胞浸润、肿瘤基质百分比及无病生存期对结直肠癌患者的诊断价值
Oncol Lett. 2017 Sep;14(3):3869-3877. doi: 10.3892/ol.2017.6639. Epub 2017 Jul 20.
9
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis.肿瘤浸润淋巴细胞在胃癌中的预后作用：一项荟萃分析。
Oncotarget. 2017 May 22;8(34):57386-57398. doi: 10.18632/oncotarget.18065. eCollection 2017 Aug 22.
10
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.SPARE的临床及患者报告结局——一项关于选择性膀胱保留术与根治性膀胱切除术的随机可行性研究
BJU Int. 2017 Nov;120(5):639-650. doi: 10.1111/bju.13900. Epub 2017 May 29.